Clinical trials: Ventricular Repolarization
Healthy Volunteer
Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults
The primary objective of Part 1 of the study is to evaluate the safety and tolerability of S-648414 after administration of a single oral dose of S-648414 in healthy adult study participants.
- Trial name
- NCT04147715
- Testing
- S-648414, Midazolam, Dolutegravir
- Where
- 2 sites in United States, Japan
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Shionogi
Ventricular Repolarization
A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects
This study is conducted to evaluate the effectiveness of DIC075V on ventricular repolarization in healthy subjects compared to placebo after a single dose of DIC075V administered intravenously (IV) and to evaluate ECG assay…
- Trial name
- NCT01812538
- Testing
- DIC075V
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Patients With Pace Makers But no Evidence of Ischemic Heart Disease
A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade
To assess the effects of GTN on QT and QTc in subjects with And without atrial pacing. This will be done with and without autonomic blockade at two different pacing rates.
- Trial name
- NCT00174512
- Testing
- GTN, Moxifloxacin
- Where
- 6 sites in Belgium, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Pfizer
Small Cell Lung Carcinoma
A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (SCLC).
- Trial name
- NCT02874664
- Testing
- Rovalpituzumab Tesirine
- Where
- 15 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Stemcentrx
Neoplasm Malignant
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Primary Objective: To assess the effect of SAR302503 (500 mg) administered as 14-day repeated doses on the QTcF interval compared to 1-day placebo in patients with advanced solid tumors.
- Trial name
- NCT01836705
- Testing
- SAR302503 (TG101348), Panolosetron
- Where
- 10 sites in United States, Belgium
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin…
- Conditions
- Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
- Trial name
- NCT01026233
- Testing
- brentuximab vedotin
- Where
- 9 sites in United States, Germany
- Volunteers
- 52 people
- Sponsor
- Seagen Inc.
Pulmonary Arterial Hypertension
Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on single and multiple ascending doses of KAR5585 in healthy adults.
- Trial name
- NCT02746237
- Testing
- KAR5585 Capsules
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Karos Pharmaceuticals
Torsades de Pointes
A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers
Determine whether VI-0521 has an effect on the electrical activity of the heart in healthy subjects. Find out how much VI-0521 is in the blood and any potential side effects on ECG's of healthy subjects after taking the study…
- Trial name
- TQT (NCT00839891)
- Testing
- VI-0521
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC